The importance of European unity for the future of pharmaceutical investments
Europe is facing a crucial challenge in maintaining its competitiveness in the global pharmaceutical sector. According to Elias Khalil, President of Lilly Italy Hub, the European Union's ability to attract new investments and promote scientific innovation depends strictly on the cohesion between its member states.
During a recent speech, Khalil emphasized that a divided Europe is unable to offer credible responses to the complex needs of the current market. For companies in the sector, political stability and the harmonization of regulations represent fundamental elements in deciding where to allocate the resources necessary for the research and development of new drugs.
The pharmaceutical sector requires long-term investment and constant collaboration between European institutions and private companies. A common policy would allow for the creation of a more favorable environment, capable of supporting researchers and accelerating patient access to the most advanced therapies by reducing bureaucratic fragmentation between different countries.
In conclusion, Khalil's appeal highlights how the strengthening of the European Union is not just a political issue, but a determining factor for technological progress and public health. Only through coordinated action will Europe be able to continue playing a leading role in the international scientific landscape, ensuring economic growth and innovation for all citizens.